SSGJ-706

Phase 2Small molecule

SShenyang Sunshine Pharmaceutical Co., LTD.

SSGJ-706 is one of 77 small molecule programs targeting Patients With Advanced Solid Tumors. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Patients With Advanced Solid TumorsNot yet recruiting

Non-Small Cell Lung CancerRecruiting

Patients With Advanced Solid TumorsPhase 1

Not yet recruiting

Non-Small Cell Lung CancerPhase 2

Recruiting

Competition

Competitive Landscape

449 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Ensacove

XXcovery Holdings, Inc.

Phase 3

8 2

Carboplatin Plus Paclitaxel

Bayer

Phase 3

2 3

HB1801

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Phase 3

2 4

SSGJ-706

SShenyang Sunshine Pharmaceutical Co., LTD.

Phase 2

1 5

Remeron

OOrganon and Co

Preclinical

1 6

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

—7

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Preclinical

—8

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Treatment

1 10

Valemetostat Tosylate

Daiichi Sankyo

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 2Recruiting

Non-Small Cell Lung Cancer

NCT07171606

Clinical

Trials by Indication[1]

Patients With Advanced Solid Tumors1 trial

Phase I Clinical Study to Evaluate the Safety and Efficacy of SSGJ-706 Monotherapy for Patients With Advanced Solid Tumors

Not yet recruiting·SSunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.·Phase 1·NCT06533605·60 enrolled

Non-Small Cell Lung Cancer1 trial

A Phase II Study of SSGJ-706 Monotherapy and Combination Therapy in Advanced Non-Small Cell Lung Cancer（NSCLC） Patients

Recruiting·SShenyang Sunshine Pharmaceutical Co., LTD.·Phase 2·NCT07171606·240 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for SSGJ-706. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SSGJ-706 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SSGJ-706. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shenyang Sunshine Pharmaceutical Co., LTD. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SShenyang Sunshine Pharmaceutical Co., LTD.

SSGJ-706

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Patients With Advanced Solid Tumors1 trial

Non-Small Cell Lung Cancer1 trial

References

Drug Info

Quick Facts

Related News